APCCC 2024: Which Patients with mHSPC Can Be Offered a Treatment Break (De-Escalation Strategies) and How to Manage the Break?
APCCC 2024 management of mHSPC, EMA established the Cancer Medicines Forum, androgen deprivation and continuing the ARTA, LIBERTAS study, EMBARK, DE-ESCALATE EORTC 2238 trial, intermittent androgen deprivation.